{"product_id":"handbook-of-contemporary-neuropharmacology-3-volume-set-hardback-9780471660538","title":"Handbook of Contemporary Neuropharmacology, 3 Volume Set (Hardback) 9780471660538","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eHandbook of Contemporary Neuropharmacology, 3 Volume Set\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eDavid R. Sibley (Editor-in-chief), DR Sibley (Author), Israel Hanin (Associate editor), Michael Kuhar (Associate editor), Phil Skolnick (Associate editor)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780471660538, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 17 April 2007\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e2992 pages\u003cbr\u003e26.9 x 20.6 x 16.8 cm, 5.874 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\"...an admirable job of bringing together many aspects of neuropharmacology in one place...well worth your while to examine it.\" (\u003ci\u003eJournal of Medicinal Chemistry\u003c\/i\u003e, September 20, 2007)\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eWritten and edited by recognized experts, this comprehensive reference is also available online via Wiley InterScience.  \u003cul\u003e \u003cli\u003eProvides a readily accessible reference for students, professionals and libraries alike.\u003c\/li\u003e \u003cli\u003eEditors are recognized authorities in the neuropharmacology and science field.\u003c\/li\u003e \u003cli\u003eComprehensive reference text for active junior and senior neurobiologists.\u003c\/li\u003e \u003cli\u003eFills an important niche as a text between research publications and clinical applications.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThe \u003cb\u003e\u003ci\u003eHandbook of Contemporary Neuropharmacology\u003c\/i\u003e\u003c\/b\u003e is an invaluable resource for principal investigators and working scientists in academia, government and industry. This three volume set it also of interest for academic physicians, postdoctoral fellows and residents, and all high-level graduate students.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePreface.  \u003cp\u003eContributors.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVOLUME 1.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I: BASIC NEUROPHARMACOLOGY.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1: Soup or Sparks: The History of Drugs and Synapses (\u003ci\u003eWilliam Van der Kloot\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 2: Synaptic Transmission: Intercellular Signaling (\u003ci\u003eJ. David Jentsch and Robert H. Roth\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 3: Synaptic Transmission: Intracellular Signaling (\u003ci\u003eR. Benjamin Free, Lisa A. Hazelwood, Yoon Namkung Michele L. Rankin, Elizabeth B. Rex, and David R. Sibley\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 4: Neuronal Nicotinic Receptors: One Hundred Years of Progress (\u003ci\u003eKenneth J. Kellar and Yingxian Xiao\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 5: Muscarinic Acetylcholine Receptors (\u003ci\u003eJürgen Wess\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 6: Norepinephrine\/Epinephrine (\u003ci\u003eMegan E. Kozisek and David B. Bylund\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 7: Dopaminergic Neurotransmission (\u003ci\u003eJohn A. Schetz and David R. Sibley\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 8: Serotonin Systems (\u003ci\u003eJohn A. Gray and Bryan L. Roth\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 9: Neuropharmacology of Histamine in Brain (\u003ci\u003eRaphae¨l Faucard and Jean-Charles Schwartz\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 10: Ionotropic Glutamate Receptors (\u003ci\u003eDavid Bleakman, Andrew Alt, David Lodge, Daniel T. Monaghan, David E. Jane, and Eric S. Nisenbaum\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 11: Metabotropic Glutamate Receptors (\u003ci\u003eJames A. Monn, Michael P. Johnson, and Darryle D. Schoepp\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 12: Pharmacology of the GABAA Receptor (\u003ci\u003eDmytro Berezhnoy, Maria C. Gravielle, and David H. Farb\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 13: Metabotropic GABA Receptors (\u003ci\u003eMartin Gassmann and Bernhard Bettler\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 14: Voltage-Gated Ion Channels (\u003ci\u003eAlex Fay, Patrick C. G. Haddick, and Lily Yeh Jan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 15: Neuropeptides (\u003ci\u003eFleur L. Strand\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 16: Neurotransmitter Transporters (\u003ci\u003eJia Hu, Katherine Leitzell, Dan Wang, and Michael W. Quick\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 17: Gaseous Signaling: Nitric Oxide and Carbon Monoxide as Messenger Molecules (\u003ci\u003eKenny K. K. Chung, Valina L. Dawson, and Ted M. Dawson\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II: MOOD DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 18: Neurobiology and Treatment of Depression (\u003ci\u003eAlexander Neumeister, Dennis S. Charney, Gerard Sanacora, and John H. Krystal\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 19: Neurotrophic Factors in Etiology and Treatment of Mood Disorders (\u003ci\u003eRonald S. Duman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 20: Antidepressant Treatment and Hippocampal Neurogenesis: Monoamine and Stress Hypotheses of Depression Converge (\u003ci\u003eAlex Dranovsky and René Hen\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 21: Neuroendocrine Abnormalities in Women with Depression Linked to the Reproductive Cycle (\u003ci\u003eBarbara L. Parry, Charles J. Meliska, L. Fernando Martinez, Eva L. Maurer, Ana M. Lopez, and Diane L. Sorenson\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 22: Neurobiology and Pharmacotherapy of Bipolar Disorder (\u003ci\u003eR. H. Belmaker, G. Agam, and R. H. Lenox\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e \u003cp\u003eCumulative Index.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVOLUME 2.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I: ANXIETY AND STRESS DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1: Neurobiology of Anxiety (\u003ci\u003eMiklos Toth and Bojana Zupan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 2: Pharmacotherapy of Anxiety (\u003ci\u003eJon R. Nash and David J. Nutt\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 3: Benzodiazepines (\u003ci\u003eHartmut Lu¨ddens and Esa R. Korpi\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 4: Neuroactive Steroids in Anxiety and Stress (\u003ci\u003eDeborah A. Finn and Robert H. Purdy\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 5: Emerging Anxiolytics: Corticotropin-Releasing Factor Receptor Antagonists (\u003ci\u003eDimitri E. Grigoriadis and Samuel R. J. Hoare\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 6: Neurobiology and Pharmacotherapy of Obsessive-Compulsive Disorder (\u003ci\u003eJudith L. Rapoport and Gale Inoff-Germain\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II: SCHIZOPHRENIA AND PSYCHOSIS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 7: Phenomenology and Clinical Science of Schizophrenia (\u003ci\u003eSubroto Ghose and Carol Tamminga\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 8: Dopamine and Glutamate Hypotheses of Schizophrenia (\u003ci\u003eBita Moghaddam and Houman Homayoun\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 9: Molecular Genetics of Schizophrenia (\u003ci\u003eLiam Carroll, Michael C. O’Donovan, and Michael J. Owen\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 10: Postmortem Brain Studies: Focus on Susceptibility Genes in Schizophrenia (\u003ci\u003eShiny V. Mathew, Shruti N. Mitkus, Barbara K. Lipska, Thomas M. Hyde, and Joel E. Kleinman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 11: Pharmacotherapy of Schizophrenia (\u003ci\u003eZafar Sharif, Seiya Miyamoto, and Jeffrey A. Lieberman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 12: Atypical Antipsychotic Drugs: Mechanism of Action (\u003ci\u003eHerbert Y. Meltzer\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III: SUBSTANCE ABUSE AND ADDICTIVE DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 13: Introduction to Addictive Disorders: Implications for Pharmacotherapies (\u003ci\u003eMary Jeanne Kreek\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 14: Dopaminergic and GABAergic Regulation of Alcohol-Motivated Behaviors: Novel Neuroanatomical Substrates (\u003ci\u003eHarry L. June and William J. A. Eiler II\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 15: Nicotine (\u003ci\u003eAugust R. Buchhalter, Reginald V. Fant, and Jack E. Henningfield\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 16: Psychostimulants (\u003ci\u003eLeonard L. Howell and Heather L. Kimmel\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 17: MDMA and Other \"Club Drugs\" (\u003ci\u003eM. Isabel Colado, Esther O’Shea, and A. Richard Green\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 18: Marijuana: Pharmacology and Interaction with the Endocannabinoid System (\u003ci\u003eJenny L. Wiley and Billy R. Martin\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 19: Opiates and Addiction (\u003ci\u003eFrank J. Vocci\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART IV: PAIN.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 20: Neuronal Pathways for Pain Processing (\u003ci\u003eGavril W. Pasternak and Yahong Zhang\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 21: Vanilloid Receptor Pathways (\u003ci\u003eMakoto Tominaga\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 22: Opioid Receptors (\u003ci\u003eGavril W. Pasternak\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 23: Advent of A New Generation of Antimigraine Medications (\u003ci\u003eAna Recober and Andrew F. Russo\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e \u003cp\u003eCumulative Index.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVOLUME 3.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I: SLEEP AND AROUSAL.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1: Function and Pharmacology of Circadian Clocks (\u003ci\u003eGabriella B. Lundkvist and Gene D. Block\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 2: Melatonin Receptors in Central Nervous System (\u003ci\u003eMargarita L. Dubocovich\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 3: Narcolepsy: Neuropharmacological Aspects (\u003ci\u003eSeiji Nishino\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 4: Hypocretin\/Orexin System (\u003ci\u003eJ. Gregor Sutcliffe and Luis de Lecea\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 5: Prokineticins: New Pair of Regulatory Peptides (\u003ci\u003eMichelle Y. Cheng and Qun-Yong Zhou\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 6: Sedatives and Hypnotics (\u003ci\u003eKeith A. Wafford and Paul J. Whiting\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II: DEVELOPMENT AND DEVELOPMENTAL DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 7: Regulation of Adult Neurogenesis (\u003ci\u003eHeather A. Cameron\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 8: Neurotrophic Factors (\u003ci\u003eFranz F. Hefti and Patricia A. Walicke\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 9: Neurotrophins and Their Receptors (\u003ci\u003eMark Bothwell\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 10: Tourette’s Syndrome and Pharmacotherapy (\u003ci\u003ePieter Joost van Wattum and James F. Leckman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 11: Neuropharmacology of Attention-Deficit\/Hyperactivity Disorder (\u003ci\u003ePaul E. A. Glaser, F. Xavier Castellanos, and Daniel S. Margulies\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 12: Psychopharmacology of Autism Spectrum Disorders (\u003ci\u003eAdriana Di Martino, Steven G. Dickstein, Alessandro Zuddas, and F. Xavier Castellanos\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III: NEURODEGENERATIVE AND SEIZURE DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 13: Stroke: Mechanisms of Excitotoxicity and Approaches for Therapy (\u003ci\u003eMichael J. O’Neill, David Lodge, and James McCulloch\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 14: Epilepsy: Mechanisms of Drug Action and Clinical Treatment (\u003ci\u003eWilliam H. Theodore and Michael A. Rogawski\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 15: Pharmacotherapy for Traumatic Brain Injury (\u003ci\u003eDonald G. Stein and Stuart W. Hoffman\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 16: Dementia and Pharmacotherapy: Memory Drugs (\u003ci\u003eJerry J. Buccafusco\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 17: Pharmacotherapy and Treatment of Parkinson’s Disease (\u003ci\u003eWing Lok Au and Donald B. Calne\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 18: Parkinson’s Disease: Genetics and Pathogenesis (\u003ci\u003eClaudia M. Testa\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 19: Invertebrates as Powerful Genetic Models for Human Neurodegenerative Diseases (\u003ci\u003eRichard Nass and Charles D. Nichols\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART IV: NEUROIMMUNOLOGY.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 20: Myelin Lipids and Proteins: Structure, Function, and Roles in Neurological Disorders (\u003ci\u003eRichard H. Quarles\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 21: Pharmacology of Inflammation (\u003ci\u003eCarmen Espejo and Roland Martin\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 22: Pharmacological Treatment of Multiple Sclerosis (\u003ci\u003eB. Mark Keegan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 23: Novel Therapies for Multiple Sclerosis (\u003ci\u003eMartin S. Weber and Scott S. Zamvil\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 24: Neuropharmacology of HIV\/AIDS (\u003ci\u003eSidney A. Houff and Eugene O. Major\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART V: EATING AND METABOLIC DISORDERS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 25: Leptin: A Metabolic Perspective (\u003ci\u003eDawn M. Penn, Cherie R. Rooks, and Ruth B. S. Harris\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 26: Ghrelin: Structural and Functional Properties (\u003ci\u003eBirgitte Holst, Kristoffer Egerod, and Thue W. Schwartz\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 27: Mechanisms Controlling Adipose Tissue Metabolism by the Sympathetic Nervous System: Anatomical and Molecular Aspects (\u003ci\u003eSheila Collins, Renato H. Migliorini, and Timothy J. Bartness\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eChapter 28: Antiobesity Pharmacotherapy: Current Treatment Options and Future Perspectives (\u003ci\u003eYuguang Shi\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e \u003cp\u003eCumulative Index.\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Chemistry [\u003ca title=\"See our other books on Chemistry\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Chemistry%20%5BPN%5D%22\"\u003ePN\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Interscience","offers":[{"title":"Brand New","offer_id":52298025861400,"sku":"9780471660538","price":800.27,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780471660538.jpg?v=1781731578","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/handbook-of-contemporary-neuropharmacology-3-volume-set-hardback-9780471660538","provider":"Freshly Printed Books","version":"1.0","type":"link"}